Topical CsA is well-studied in DED showing superior efficacy & higher responder rates vs. other therapies.
CsA 0.05% twice daily with artificial tear (AT) consistently improved symptoms & staining, outperforming vehicle or AT alone across trials.
An 80-year-old man on long-term cyclophosphamide for macroglobulinemia developed pulmonary arterial hypertension. After drug withdrawal, salt restriction, and tadalafil therapy, he showed improved dyspnea, reduced edema, and better hemodynamics.